Cobenfy Prior Authorization Guide: Requirements by Payer (2025–2026)

Cobenfy (xanomeline and trospium chloride) is the first new antipsychotic mechanism approved for schizophrenia in over three decades. Unlike every prior antipsychotic — typical or atypical — it does not block dopamine D2 receptors. It targets muscarinic M1 and M4 receptors through its xanomeline component, with trospium chloride added to neutralize peripheral anticholinergic side effects that made xanomeline unviable as a standalone drug in earlier trials. That mechanism distinction matters for prior authorization in a specific way: payer step-therapy criteria for antipsychotics were written for D2 antagonists. Requiring a patient to fail a D2 blocker before accessing a drug that works through a completely different receptor class is the clinical equivalent of requiring beta-blocker failure before prescribing an ACE inhibitor.

This guide covers what makes Cobenfy PAs different, what each major payer requires, how to argue around the D2 step-therapy mismatch when it applies, and what the correct dispensing picture looks like.

Freshness notice: Cobenfy was FDA-approved September 26, 2024. Payer policies are actively being developed: UHC updated its criteria through an annual review in March 2026 (effective 6/1/2026); Cigna has published no drug-specific Cobenfy policy as of this guide; FEP Blue operates under a general CVS Caremark template rather than a dedicated policy. Requirements below reflect primary-source research as of June 2026. Verify against each payer’s current published policy before submitting.

Why Cobenfy PAs Are Different

The D2 step-therapy trap. Payer step-therapy requirements for antipsychotics presuppose a D2 mechanism. The standard criteria — fail two or three atypical antipsychotics — were drafted when every drug in the class worked the same way. Cobenfy’s M1/M4 mechanism is not on that spectrum. A patient who cannot tolerate D2 blockade due to tardive dyskinesia, NMS history, or severe metabolic syndrome from prior atypicals may have a legitimate first-line clinical case for Cobenfy, but payer criteria won’t auto-recognize it. The bypass has to be built explicitly.

ICER cost-effectiveness concern is influencing formulary placement. In 2025, ICER voted 10-2 that Cobenfy was not proven superior to generic aripiprazole (~$540/year) at its list price of ~$22,500/year. This finding has materially influenced restrictive formulary placement at some plans. The clinical counter-argument is that aripiprazole is a D2 partial agonist — comparing it to a drug with an orthogonal mechanism misframes the clinical question for patients who are specifically not candidates for D2 blockade. Document why the patient is not a candidate for standard D2 agents.

Step therapy is not uniform. For a single drug with one indication, payers landed on 0, 1, 2, and 3 required prior antipsychotic failures. There is no industry consensus — the correct answer is payer-specific, and submitting the wrong step count is the most common denial cause.

FDA Approval and Indication

Approved: September 26, 2024 (NDA 216158)

Indication: Schizophrenia in adults

Drug class: First-in-class muscarinic agonist antipsychotic — M1/M4 muscarinic receptor agonist (xanomeline component) with peripheral anticholinergic protection (trospium chloride component). Not a dopamine D2 receptor antagonist.

Formulation: Oral capsules. Three strengths:

• 50 mg/20 mg — starting strength (titration, Days 1–2)
• 100 mg/20 mg — intermediate (titration, Days 3–4)
• 125 mg/30 mg — maintenance (Day 5 onward)

Dosing and titration:

• Days 1–2: 50 mg/20 mg twice daily
• Days 3–4: 100 mg/20 mg twice daily
• Day 5 and beyond: 125 mg/30 mg twice daily (target/maintenance dose)

Maximum dose: 125 mg/30 mg twice daily. Starter pack (NDC 0003-5200-56) contains the 50/20 and 100/20 strengths for the first four days of titration.

What Cobenfy is NOT approved for: Bipolar disorder. Major depressive disorder. Alzheimer’s agitation (an active clinical trial area but not an approved indication as of this guide). Adjunctive therapy — a Phase 3 trial (ARISE) of Cobenfy as add-on therapy to atypical antipsychotics failed its primary endpoint. Cobenfy’s approved use is as monotherapy for schizophrenia in adults. Pediatric patients are not included in the approved indication.

Dispensing: Cobenfy is an oral capsule dispensed at retail pharmacies — CVS, Walgreens, Kroger, and community pharmacies can stock and dispense it. There is no REMS program, no controlled substance scheduling, and no manufacturer-imposed limited-distribution requirement. Some plan designs route it through specialty mail-order due to specialty cost-tier placement (Tier 4/5 on most formularies), but this is a plan decision, not a manufacturer requirement. “Specialty tier” here refers to the cost-sharing structure — coinsurance rather than a flat copay — not a restriction on which pharmacy can dispense it.

Diagnosis Documentation

Required ICD-10: F20.x (schizophrenia). Key codes:

• F20.0: Paranoid schizophrenia
• F20.1: Disorganized schizophrenia
• F20.2: Catatonic schizophrenia
• F20.3: Undifferentiated schizophrenia
• F20.5: Residual schizophrenia
• F20.81: Schizophreniform disorder
• F20.9: Schizophrenia, unspecified

NOT appropriate: F25.x (schizoaffective disorder) may or may not qualify depending on payer. F31.x (bipolar) and F32.x/F33.x (MDD) will be denied — Cobenfy is not FDA-approved for those indications.

PANSS or CGI score: Not required at PA submission by any payer whose primary-source criteria were verified in this research. Obtaining a baseline PANSS is good clinical practice and supports reauthorization documentation, but it is not a PA gate at initial submission.

Contraindications That Affect PA

Document any of the following explicitly — they form the clinical basis for bypassing D2-based step-therapy requirements where applicable.

Anticholinergic burden (drug interaction, not contraindication): Trospium adds anticholinergic load. Patients on bladder anticholinergics, first-generation antihistamines, TCAs, or low-potency antipsychotics carry elevated burden. Document in the medication list.

Who Covers Cobenfy

Payer-Specific PA Requirements

Cigna / Evernorth

Source: Cigna Coverage Policy 1602 “Drugs Requiring Medical Necessity Review for Employer Plans,” effective 3/15/2025 (May 2025 archived version)

Coverage: Yes. Cigna added Cobenfy to Policy 1602 effective March 15, 2025.

Criteria (any one of the following):

1. Patient has tried two prior atypical antipsychotics (from open list including generics and branded: risperidone, olanzapine, quetiapine, quetiapine XR, aripiprazole, paliperidone ER, ziprasidone, Fanapt, Latuda, Rexulti, asenapine, Caplyta)
2. Patient has already started therapy with Cobenfy
3. Patient has taken Cobenfy at any time in the past

No minimum trial duration — “tried” is the stated standard. No minimum weeks requirement.

The auto-bypass paths (criteria 2 and 3) are clinically valuable: any prior Cobenfy use — including samples, bridge supply, or fills under a prior plan — bypasses the two-failure step entirely.

No PANSS, no psychiatric evaluation required. Both generics and branded atypicals count toward the two-step requirement (broader list than UHC’s closed list of five generics).

Access note: Cigna stripped the full criteria table from the publicly accessible Policy 1602 PDF in mid-2026 — the complete criteria now requires provider portal login at CignaForHCP.com. The two-antipsychotic requirement is confirmed from the May 2025 archived version; verify current criteria have not changed via portal before submitting.

Approval duration: 12 months.

UnitedHealthcare / OptumRx

Source: UHC PA/Medical Necessity Policy Program 2026 P 2360-2 (Cobenfy commercial), effective 6/1/2026; UHC Quantity Limits per Duration, effective 6/1/2026

Coverage: Yes. Not in UHC’s commercial PDL (confirmed from both Sept 2025 and Jan 2026 PDLs). Accessed exclusively through the PA/Medical Necessity pathway.

Criteria (all required):

• Confirmed schizophrenia diagnosis, age ≥18
• Failure, contraindication, or intolerance to three (3) atypical antipsychotics from this closed list of five:
  • Aripiprazole, olanzapine, quetiapine (IR or ER), risperidone, ziprasidone
• Document each: drug name, date, and duration of trial
• No minimum trial duration specified

The list is closed. Failures of paliperidone, asenapine, lurasidone, Caplyta, Vraylar, or other antipsychotics do not count.

Bypass pathways:

• Behavioral inpatient initiation within past 3 months + currently stable — submit discharge summary with Cobenfy on medication list
• New to plan within 120 days + already stabilized on Cobenfy — provide prior PA documentation

Quantity limit: 60 capsules/30 days (maintenance). Starter pack: 1 per year.

Approval duration: 12 months initial; 12 months reauthorization (documentation of “positive clinical response” required).

Aetna

Sources: Aetna 2025 Standard Plan formulary (12/01/2025); CVS Caremark PA logic form 6688-D (P10-2025); CVS Caremark PA fax form 6685-A v2 (02/01/2025); Aetna Policy 1340-A P10-2024_R (Cobenfy not listed)

Coverage: Yes. Tier: NPB (Non-Preferred Brand). No standalone Aetna clinical policy exists for Cobenfy. CVS Caremark administers Aetna’s pharmacy benefit.

The 180-day auto-pay rule:

If the patient has filled any antipsychotic for a 30-day supply in the past 180 days under a CVS Caremark-administered benefit, the claim auto-processes — no PA required. Patients switching from any other antipsychotic to Cobenfy qualify automatically.

If PA is triggered (antipsychotic-naive or no fill in 180 days):

• CVS Caremark 6688-D: sole stated criterion = schizophrenia diagnosis
• PA fax form 6685-A:
  • Q2 (hard gate): Failure, intolerance, or contraindication to one generic atypical (aripiprazole, asenapine, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone) — “if no → no further questions” = effective denial
  • Q3 (advisory): Branded atypical trial asked; no hard termination if answered “no”

No PANSS, no psychiatric evaluation required. Approval duration: 12 months.

BlueCross BlueShield / FEP

Sources: FEP Blue 2026 formulary; CVS Caremark 6688-D; BCBS Arizona P346.1 (1/1/2026); Wellmark BCBS Policy 05.05.70 (6/27/2025); Highmark December 2024 formulary update; Centene CP.PMN.299 (1/1/2025)

FEP Blue (Federal Employee Program): Not on 2026 FEP formulary; no dedicated FEP policy. Governed by CVS Caremark 6688-D criteria — same 180-day auto-pay path as Aetna; schizophrenia diagnosis if PA triggered. Auth: 12 months.

Regional BCBS plans vary significantly. Pull the plan-specific formulary before submitting.

Wellmark BCBS (Iowa/South Dakota) — Policy 05.05.70 (updated 6/27/2025):

• No step therapy. Criteria: age ≥18 + confirmed schizophrenia diagnosis (or inpatient-initiation continuation)
• Quantity limit: 60 capsules/30 days. Auth: 12 months.

BCBS Arizona — Policy P346.1 (effective 1/1/2026):

• Step therapy: failure, intolerance, inadequate response, or contraindication to one prior antipsychotic from: aripiprazole, risperidone, olanzapine, clozapine, or quetiapine
• Monitoring required: Baseline and ongoing liver enzymes, bilirubin, and heart rate
• Excludes treatment-resistant schizophrenia (item 10) — this plan will not cover Cobenfy for TRS patients
• No moderate/severe hepatic impairment; no concurrent anticholinergic agents. Auth: 12 months.

Centene / Health Net — CP.PMN.299 (effective 1/1/2025):

• Step therapy: two failures — (1) aripiprazole specifically AND (2) one of: risperidone, quetiapine, olanzapine, or ziprasidone; each at maximum indicated dose for at least 4 weeks
• Metabolic bypass: Documented diabetes mellitus OR BMI >30 bypasses step therapy — include lab values or BMI measurement in initial submission
• State law bypass: Step-therapy override states receive exceptions per state law
• Illinois HB 5395: Removes step therapy entirely for IL members as of 1/1/2026
• Auth: 12 months.

Highmark (PA, WV, DE, NY): Non-formulary (NF) as of December 2024. Listed in “Products Not Added” across Comprehensive, Core, and National Select formularies. Medical or formulary exception required.

BCBS MA, BCBS TX, BCBS FL, BCBS IL, BCBS MI: No published standalone Cobenfy PA criteria found as of June 2026. Confirm plan-specific formulary status directly.

Medicare Part D

Sources: CMS-4180-F (protected class rule); Medicare research synthesis, June 2026

Coverage: Yes. Antipsychotics are one of CMS’s six protected drug classes — all Part D plans must include Cobenfy. Typical placement: Tier 4 or Tier 5 (specialty cost tier).

Important distinction: Unlike antiretrovirals (no PA allowed), antipsychotics permit step therapy and PA for new starts under CMS rules. Protected class means the drug is on the formulary, not that access is unrestricted.

The established patient rule (CMS-4180-F): Plans may not impose step therapy or PA on a beneficiary already stabilized on Cobenfy. Document prior use — prior fills under any plan bypass the new-start step requirement.

For new starts (modal Medicare Advantage criteria):

• Confirmed schizophrenia diagnosis, age ≥18
• Failure or intolerance/contraindication to two prior generic atypical antipsychotics (aripiprazole, asenapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)
• Psychiatrist documentation required on some MA plans
• Auth: 12 months

2026 cost structure: Deductible up to $615 → specialty tier coinsurance → $2,100 OOP cap (IRA, inflation-indexed from 2025’s $2,000). At ~$1,887/month, a patient hits the cap within two fills. M3P (Medicare Prescription Payment Plan) available to spread OOP across monthly installments. LIS/Extra Help: ~$12.15/fill. BMS copay card not eligible for Medicare beneficiaries.

The D2 Step-Therapy Problem

All prior antipsychotics block dopamine D2 receptors. Payer step-therapy criteria were written with this assumption embedded: if you haven’t failed a D2 antagonist, you haven’t tried first-line antipsychotics. Cobenfy’s antipsychotic effect works through muscarinic M1 and M4 agonism — not D2 blockade. The mechanisms do not overlap.

Clinical situations that support D2 step-therapy bypass:

The peer-to-peer argument: “Requiring failure of a D2 dopamine antagonist before approving a muscarinic M1/M4 agonist is like requiring beta-blocker failure before prescribing an ACE inhibitor — the mechanisms are orthogonal. This drug does not share the receptor target that the step-therapy criteria assume.”

Responding to the ICER comparison: Payers may cite the 10-2 ICER vote (Cobenfy not proven superior to generic aripiprazole) as cost-justification for step therapy. The counter-argument: the question is not whether Cobenfy is superior to aripiprazole in general — it is whether Cobenfy is appropriate for this patient who is not a candidate for D2 blockade. Document the contraindication to D2 antagonists specifically.

State step-therapy laws: 34+ states have enacted step therapy reform laws requiring exception pathways for contraindication or established prior therapy. These apply to state-regulated commercial plans; ERISA self-funded employer plans are generally exempt. Most require plan response within 72 hours (standard) or 24 hours (expedited). Note: Florida’s schizophrenia/SMI step-therapy exemption (SB 534/SB 112) applies to Medicaid only — commercial plans are not covered.

Tips for First-Pass Approval

1. Match the step count to the payer. Wellmark: 0. CVS Caremark plans (Aetna, FEP): 0 if antipsychotic fill in 180 days. BCBS AZ: 1. Cigna: 2 (any 2 atypicals, no minimum duration). Centene: 2 (aripiprazole + 1 other, ≥4 weeks each). UHC: 3 from its closed list of 5 generics.

2. For Aetna and FEP Blue: get the 180-day claims history first. Any antipsychotic fill for a 30-day supply in the past 180 days = no PA needed.

3. For UHC: the step list is closed to five drugs. Document only aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone. Branded atypicals and other generics do not count.

4. For Centene plans: document metabolic status at initial submission. Diabetes or BMI >30 bypasses step therapy entirely — include lab values or BMI measurement upfront.

5. Document TD or NMS history in the initial submission. These are the strongest D2 bypass arguments — don’t wait for the appeal to introduce them.

6. For UHC: use the inpatient bypass if applicable. Cobenfy started during a behavioral inpatient admission within the past 3 months + patient is currently stable = submit discharge summary and bypass the three-failure step entirely.

7. For Medicare: establish new vs. established patient status. Prior Cobenfy use under any prior plan triggers CMS-4180-F established patient protection. Document prior fills with pharmacy records or prescriber letter.

8. COBENFY Cares before the first denial. BMS’s patient access program (1-877-262-3639) provides PA support, bridge supply, and copay card for commercially insured patients (may pay $0/month). Not available for Medicare/Medicaid/TRICARE patients.

9. Confirm schizophrenia ICD-10. F20.x required. F31.x (bipolar) and F32.x/F33.x (MDD) will be denied.

10. Cobenfy is monotherapy only. The ARISE adjunctive trial failed its Phase 3 endpoint. Do not submit a PA for adjunctive use — it is not on the FDA label.

When the PA Fails

Sources

• FDA Approval Letter, Cobenfy (NDA 216158), September 26, 2024
• Bristol-Myers Squibb Prescribing Information — Cobenfy (xanomeline and trospium chloride), 2024
• DailyMed — COBENFY (setid: 8f0e73bf-6025-44f6-ab64-0983322de0df)
• UHC PA/Medical Necessity Policy Program 2026 P 2360-2 (Cobenfy commercial), effective 6/1/2026
• UHC Quantity Limits per Duration, effective 6/1/2026
• CVS Caremark PA Logic Form 6688-D — Cobenfy, version P10-2025
• CVS Caremark PA Fax Form 6685-A — Cobenfy, version 2, 02/01/2025
• Cigna Step Therapy Policies ph_1801 and ph_1802; Cigna CNF A-Z index, accessed June 2026
• Aetna 2025 Standard Plan Formulary (catalog date 12/01/2025); Aetna Policy 1340-A P10-2024_R
• Wellmark BCBS Policy 05.05.70 (updated 6/27/2025)
• BCBS Arizona Policy P346.1 (effective 1/1/2026)
• Highmark December 2024 Formulary Update
• Centene / Health Net Clinical Pharmacy Policy CP.PMN.299 (effective 1/1/2025)
• CMS-4180-F — Medicare Advantage and Part D Drug Pricing Final Rule
• ICER — Final Evidence Report on Treatment for Schizophrenia, 2025

PA requirements update frequently. This guide was last reviewed June 2026. Always verify against each payer’s current published policy before submitting.